SCHEMBL7044147

SCHEMBL7044147

CC[Si](CC)(CC)O[C@@H](CNCC(C(=O)Nc1ccccc1)c1ccc(OC)c(OC)c1)c1ccc(OCc2ccccc2)c(NS(C)(=O)=O)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADRB3 P13945 13/20 0.42
▸ F2 P00734 3/20 0.40
▸ F10 P00742 3/20 0.40
▸ PRSS1 P07477 3/20 0.40
▸ F7 P08709 3/20 0.40
▸ ADRB2 P07550 5/20 0.39
▸ ADRB1 P08588 4/20 0.39
▸ ESRRA P11474 1/20 0.39
▸ PRSS2 P07478 1/20 0.38
▸ F3 P13726 1/20 0.38
▸ PRSS3 P35030 1/20 0.38
▸ TRPV1 Q8NER1 1/20 0.38
▸ CTSV O60911 1/20 0.38
▸ CTSL P07711 1/20 0.38
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ ACHE P22303 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7036245 0.89 ADRB3 (0.42) ADRB3F2F10PRSS1F7
SCHEMBL6986483 0.82 ADRB3 (0.48) ADRB3F2F10PRSS1F7
SCHEMBL7038384 0.81 ADRB3 (0.60) ADRB3ADRB2ADRB1
SCHEMBL7038435 0.78 ADRB3 (0.52) ADRB3ADRB2ADRB1
SCHEMBL7038441 0.78 ADRB3 (0.52) ADRB3ADRB2ADRB1
SCHEMBL4817546 0.77 CYP19A1 (0.44) ADRB3F2F10PRSS1F7
SCHEMBL6479480 0.77 CYP19A1 (0.44) ADRB3F2F10PRSS1F7
SCHEMBL5483348 0.77 CYP19A1 (0.44) ADRB3F2F10PRSS1F7
SCHEMBL7605339 0.77 CYP19A1 (0.44) ADRB3F2F10PRSS1F7
SCHEMBL7605348 0.77 CYP19A1 (0.44) ADRB3F2F10PRSS1F7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0659737-B1 Catecholamine surrogates useful as beta 3 agonists BRISTOL MYERS SQUIBB CO (US) 2003-03-26 — — EP disclosed
EP-0659737-A2 Catecholamine surrogates useful as B3 agonists BRISTOL-MYERS SQUIBB COMPANY (US) 1995-06-28 — — EP disclosed
Send feedback